In the phase 3, randomized, placebo-controlled trial (ASTRA), compared to RAI alone, Selumetinib plus adjuvant RAI, 18 months after RAI, there was no statistically significant change in the CR rate (Selumetinib, n = 62 [40%]; placebo, n = 30 [38%]; odds ratio, 1.07 [95% ...